Parexel International (PRXL) 25.21 1.06

Parexel International Corp
(PRXL) 25.21 1.06

Last Trade:	25.21	Day Range:	24.4527 - 25.22
Trade Time:	12:02PM	52wk Range:	15.26 - 27.91
Prev. Close:	24.15	Market Cap:	1.49B
Open:	24.47	Div Yield:	0
Volume:	193036	PE:
EPS:	0.60

The Latest On PRXL

UPDATE: Goldman Sachs Raises Target to $19 on PAREXEL International 2/1/12 8:54am

Parexel Up 10% After Earnings Miss 1/31/12 9:16am

PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts 1/17/12 6:43am

PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology 11/22/11 6:56am

UPDATE: Disclosure Insight Upgrades Rating to Medium Risk – Positive Bias on Parexel International 11/17/11 6:55am

UCB and PAREXEL Sign Strategic Partnership Agreement 11/15/11 1:11pm

PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value 10/25/11 5:55am

Market Winners 8/10/11 2:35pm

UPDATE: Jefferies Upgrades PAREXEL Int'l to Hold 8/10/11 7:33am

Jefferies Upgrades PAREXEL To Hold 8/10/11 4:56am

UPDATE: Jefferies Downgrades Parexel from Buy to UNDERPERFORM and Lowers PT from $29.00 to $19.50 7/21/11 9:32am

Jefferies Downgrades PAREXEL to Underperform from Buy 7/21/11 6:15am

UPDATE: Goldman Sachs Raises Target to $19 on PAREXEL International 2/1/12

Parexel Up 10% After Earnings Miss 1/31/12

PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts 1/17/12

PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology 11/22/11

UPDATE: Disclosure Insight Upgrades Rating to Medium Risk – Positive Bias on Parexel International 11/17/11

UCB and PAREXEL Sign Strategic Partnership Agreement 11/15/11

PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value 10/25/11

Market Winners 8/10/11

UPDATE: Jefferies Upgrades PAREXEL Int'l to Hold 8/10/11

Jefferies Upgrades PAREXEL To Hold 8/10/11

UPDATE: Jefferies Downgrades Parexel from Buy to UNDERPERFORM and Lowers PT from $29.00 to $19.50 7/21/11

Jefferies Downgrades PAREXEL to Underperform from Buy 7/21/11

Who Wants to Buy Some Drugs? 7/19/11

Top 4 Small-Cap Stocks In The Medical Laboratories & Research Industry With The Highest EPS Estimates (ICLR, PRXL, BRLI, MTOX) 4/19/11

Top 4 Small-Cap Stocks In The Medical Laboratories & Research Industry With The Highest Revenue (PRXL, ICLR, AIQ, BRLI) 3/15/11

Fast Money Picks For August 17th (PRXL, MO, GENZ, TJX) 8/16/10

PRXL Introduces FY2011 Guidance In Line With Expectations 6/3/10

Benzinga’s Volume Movers (VLTR, AMLN, PRXL, ICLR, ZION) 1/26/10

Benzinga’s Volume Movers (MAPP, RICK, VOLC, PRXL, AMAG) 1/11/10

Benzinga’s Volume Movers (DRWI, OSIS, PRXL, TEVA, ASEI) 1/8/10

UPDATE: Goldman Sachs Raises Target to $19 on PAREXEL International 2/1/12

UPDATE: Disclosure Insight Upgrades Rating to Medium Risk – Positive Bias on Parexel International 11/17/11

Market Winners 8/10/11

UPDATE: Jefferies Upgrades PAREXEL Int'l to Hold 8/10/11

Jefferies Upgrades PAREXEL To Hold 8/10/11

UPDATE: Jefferies Downgrades Parexel from Buy to UNDERPERFORM and Lowers PT from $29.00 to $19.50 7/21/11

Jefferies Downgrades PAREXEL to Underperform from Buy 7/21/11

Jefferies Downgrades ICLR, PRXL 7/21/11

Piper Jaffray Reports on PAREXEL International 6/3/11

Piper Jaffray Raises PT On PAREXEL To $20 6/3/11

Jefferies Comments On Parexel Guidance 6/2/11

Goldman Sachs Provides Color on CROs, Sell Parexel and Buy Pharmaceutical Product Development 5/23/11

Trade PRXL
NOW!

Partner Headlines

PAREXEL International Corp. (PRXL) COO Mark A Goldberg sells 6,000 Shares 2/3/12

Biotechs, HMOs, Digital Records Push Aid Health Stocks 1/19/12

The Long-Term Play In Lab Work (BBH, CRL, ICLR, PRXL, WX) 1/16/12

Aggressive Growth Stock Picks-Oct.11, 2011 - Zacks Rank Buys 10/11/11

PAREXEL International - Aggressive Growth 10/10/11

PPD Goes Private (PPDI, CVD, PRXL, CRL, ICLR, ERT, PFE, MRK) 10/5/11

First Energy, Riverbed: Analysts' New Ratings 7/21/11

Company News for May 24, 2011 - Corporate Summary 5/24/11

Parexcel: Great Growth but a Tough Business

Parexel: Great Growth but a Tough Business

PAREXEL International Corp. Reports Operating Results (10-K)

Press Releases

PAREXEL Expands Global Clinical Logistics Capabilities to Support More Efficient Trial Execution 2/8/12 Newswire Story

PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 2/6/12 Newswire Story

PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 2/1/12 Newswire Story

PAREXEL Reports Second Quarter Fiscal Year 2012 Financial Results 1/30/12 Newswire Story

PAREXEL Expands Alliance Network to Support Early Phase Patient Studies, Establishes Collaboration With University Hospitals Bristol NHS Foundation Trust 1/23/12 Newswire Story

Perceptive Informatics® Medical Imaging Services Receive Top Ratings 1/18/12 Newswire Story

PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts 1/17/12 Newswire Story

PAREXEL International to Present at J.P. Morgan Healthcare Conference 1/9/12 Newswire Story

PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call 1/3/12 Newswire Story

PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes 12/21/11 Newswire Story

Perceptive Informatics® DataLabs® EDC Solution Implemented by 15 of the Top Global Biopharmaceutical Companies 12/19/11 Newswire Story

Perceptive Informatics Completes Over 500 System Integrations as the Biopharma Industry Continues to Adopt Seamless eClinical Solutions 12/15/11 Newswire Story

Get the latest PRXL stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Parexel International Corp stock price.

Parexel International Corp by YCharts